On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...

The FDA has approved a fixed-dose triple combination therapy for the maintenance treatment of asthma in adults and children aged 12 years and older, according to a press release from manufacturer ...

The FDA approved Breztri Aerosphere, a single-inhaler triple therapy, as a maintenance treatment for patients aged at least ...

Affinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army ...

Sanofi SA (NASDAQ:SNY) on Tuesday shared progress from its mid- to late-stage respiratory pipeline. The French drug maker reported preliminary results from the TIDE-Asthma phase 2 study of amlitelimab ...

Breztri becomes the first single-inhaler triple therapy for patients as young as 12 years ...

Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...

In many cultures, it is common to burn incense for religious and cultural practices, including meditations, celebrations and spiritual and ancestral worship. A new medically challenging case being ...

Adults with moderate to severe asthma with uncontrolled symptoms had significantly improved asthma control with daily oral ...

Timing transforms outcomes For people living with severe asthma, outcomes are not determined only by what treatment they ...

Sept 6 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive ...